Gilead – 2026Q1 results
Here is the summary of Gilead Sciences’ (NASDAQ: GILD) Q1 2026 financial results announced on May 7, 2026. Core Financial Performance Metric Q1 2026 Q1 2025 YoY Change Total Revenue 6.96B 6.67B 4.4% Net Income 2.02B 1.32B 53.7% GAAP Diluted EPS $1.61 $1.04 54.8% Non-GAAP Diluted EPS $2.03 $1.81 12.2% Product & Segment Breakdown Full-Year […]
Gilead – History and Competition
The history of Gilead Sciences can be divided into four distinct phases, tracking its evolution from a focused antiviral biotech startup into a global multi-therapeutic pharmaceutical giant. Phase 1: Foundation and Early Discovery (1987-2000) Phase 2: Establishing HIV Market Dominance (2001-2010) Phase 3: The Hepatitis C Breakthrough and Revenue Peak (2011-2016) Phase 4: Diversification, Oncology, […]